Patent: 7,597,889

Summary for Patent: 7,597,889

Title:	Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
Abstract:	Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and/or Fc.gamma.RIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.
Inventor(s):	Armour; Kathryn Lesley (Cambridge, GB), Clark; Michael Ronald (Cambridge, GB), Williamson; Lorna McLeod (Cambridge, GB)
Assignee:	Cambridge Enterprise Limited (Cambridge, GB)
Application Number:	09/674,857
Patent Claims:	see list of patent claims

Details for Patent 7,597,889

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Greer Laboratories, Inc.	N/A	insects (whole body), mite dermatophagoides pteronyssinus	Injection	101835	09/15/1958		2018-05-08
Allermed Laboratories, Inc.	N/A	insects (whole body), mite dermatophagoides pteronyssinus	Injection	102213	03/12/1974		2018-05-08
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2018-05-08
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2018-05-08